Greetings. Welcome to the Reliance Global Group Fourth Quarter Business Update Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Ted Ayvas, Investor Relations. Ted, you may begin.

Thanks, Paul. Good afternoon, and thank you for joining Reliance Global Group's 2025 Fourth Quarter and Year-end Financial Results and Business Update Conference Call. On the call with us today are Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group; and Joel Markovits, Chief Financial Officer of Reliance. Earlier today, the company announced its operating results for the quarter ended December 31, 2025, and the press release is posted on the company's website, www.relianceglobalgroup.com. In addition, the company will be filing its annual report on Form 10-K with the U.S. Securities and Exchange Commission today, which can also be accessed on the company's website as well as the SEC's website, www.sec.gov. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at (212) 671-1020. Before Mr. Beyman reviews the company's operating results for the quarter ended December 31, 2025, we would like to remind everyone that this conference call may contain forward-looking statements. All statements other than statements of historical facts contained in this conference call, including statements regarding our future results of operations and financial position, strategy and plans and our expectations for future operations are forward-looking statements. The words anticipate, estimate, expect, project, plan, seek, intend, believe, may, might, will, should, could, likely, continue, design and the negative of such terms and other words in terms of similar expressions are intended to identify forward-looking statements. These forward-looking statements are based largely on the company's current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to several risks, uncertainties and assumptions as described in the company's Form 10-K filed with the U.S. Securities and Exchange Commission. Because of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in the conference call may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance or achievements. In addition, neither the company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The company disclaims any duty to update any of these forward-looking statements. All forward-looking statements attributable to the company are expressly qualified in their entirety by these cautionary statements as well as others made on this conference call. You should evaluate all forward-looking statements made by the company in the context of these risks and uncertainties. Having said that, I would now like to turn the call over to Mr. Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. Ezra?

Thanks, Ted. Good afternoon, and thank you to everyone for joining us today. When I think about 2025, what stands out most is the progress we've made reshaping the company for the future. Over the past year, we focused on strengthening the foundation of the business while beginning to execute on a broader strategy designed to expand Reliance beyond this traditional insurance routes and into a technology-driven growth platform. In simple terms, our strategy is built around two complementary pillars. The first is our insurance and InsurTech platform, which provides recurring revenue, strong industry relationships and a stable operational foundation. The second is EZRA International Group and the Scale51 model, which allows us to identify innovative technology companies and build meaningful ownership positions as those businesses grow and scale. Together, these pillars are designed to give Reliance both operating stability and exposure to emerging technology opportunities that we believe can create long-term value. At the center of that strategy, is the Scale51 operating model, which operates within our EZRA International Group platform. Scale51 is designed to identify innovative technology companies, acquire meaningful ownership positions and actively support their growth as they scale into global markets. By leveraging our public company platform, operational expertise and strategic relationships, we aim to help promising technologies move from early innovation to scalable commercial businesses. Through this model, we are targeting sectors where innovation and long-term growth opportunities are accelerating, including cybersecurity, artificial intelligence, fintech and digital health. While Scale51 represents an important expansion of our strategy, it is built on a business that continues to generate stable operating performance. Our insurance and InsurTech operations serve as the operational backbone of the company, generating recurring revenue while supporting our long-term initiatives. In 2025, these operations generated more than $12 million in commission income, demonstrating the…

Thank you very much, Ezra, and good afternoon, everyone. I appreciate you joining today's call. It will be my pleasure to walk through some of our key financial highlights for the year ended December 31, 2025. Unless otherwise noted, all figures discussed are approximate. Our financial priorities during 2025, were centered on strengthening our balance sheet, improving liquidity and positioning the company for disciplined long-term growth. As Ezra mentioned earlier, 2025 was an important transition year for us. During the year, we executed a portfolio realignment through the asset sales of our subsidiaries, Fortman Insurance Services, Employee Benefits Solutions and U.S. Benefits Alliance. These transactions allowed us to reduce debt, strengthen our balance sheet and simplify our operating structure as we reposition the business to support our Scale51 technology growth strategy. Importantly, our insurance brokerage and InsurTech platforms continue to provide a stable operating foundation, which we believe positions the company well as we pursue this next phase of growth. Let's begin with a quick look at the balance sheet compared with year-end 2024. Unrestricted cash increased $0.9 million or 250% to $1.3 million at December 31, 2025, compared with $0.4 million a year ago. Working capital improved by $1.5 million or 351% to $1.9 million. Stockholders' equity increased $3.4 million or 114% to $6.4 million. These improvements reflect our continued focus on strengthening our financial position and maintaining the flexibility needed to support our future growth initiatives. Turning to the income statement. Commission income totaled $12.4 million for the year ended December 31, 2025, compared with $14.1 million in 2024. The decrease primarily reflects our strategic portfolio realignment during the year with the divestitures of subsidiaries previously mentioned. Commission expense was $4.6 million compared with $4.2 million in 2024, the increase primarily reflects higher commissions associated with increased sales…

[Operator Instructions] And the first question today is coming from [ Nicole Kaufman from BlackRidge. ]

Congratulations on the progress. My first question is around Scale51, and you spent some time during the call discussing this initiative, which sounds like an exciting new direction for the company. But can you share a bit more about what investors should expect from the Scale51 strategy over the next 6 to 12 months?

Okay. I mean I think in a very short phrase, and I'll elaborate a little more, positive, big, good excitement. Which should translate into bottom lines as well. We're focusing on not very young companies, which have less promise, but companies that somewhat already show either close to revenue or accomplishing certain things and usually, yes, close to revenue. And we've talked to a lot of companies before we zero in, and we think that we're off to a good start, both with Enquantum, which we've already closed and what we're seeing and the excitement about that -- it's really -- it's more major actually than we realized during due diligence, we discovered it was better than we thought. And it's getting exciting. We hope to share that as things progress as milestones are achieved, and that's part of the -- our policy and philosophy is, we're not just handing over checks. There have to be -- milestones have to be achieved for us to make payments or investments. And so far, that's working, and we look forward to a lot more.

Well, thank you for expanding on that for me. And during the call, you also highlighted the growing need for post-quantum encryption technologies. Where is Enquantum currently in terms of product development and commercialization? And what kind of time line might investors expect before the company begins generating revenue?

The truth is, we're excited to say that revenue is quite possible even within the year. Even later this year, believe they're working on a few years, and we're coming to the point where -- and we have the team that's there, and we have very strategic people and the team that are -- we're working towards revenue, hopefully even later this year. And I will say that I'm not sure everyone appreciates what quantum computing is. But quantum computing is, we're talking about as fast as you think you get your computing today, quantum computing that's being worked on worldwide is about 10,000x quicker than existing computing. That could tell you why it's so, so crucial and important to have something that protects the encryptions that you have. All the codes and things that are today will be meaningless with that type of computing that could be broken in seconds. So this -- and we're learning more as we have this team and they really know what they're doing in execution. The due diligence team was extremely overwhelmingly impressed by the team of Enquantum. And it's getting exciting, really. We hope that it will translate into dollars and cents soon, but it's a really exciting development that's needed for the world, and it will be good for Reliance and for EZRA International Group.

Yes, I'm looking forward to that. My last question is around the Scentech opportunity, which sounds really interesting and particularly the non-invasive breath analysis technology. Can you expand on what makes Scentech's approach unique and what you believe differentiates it from other diagnostic technologies currently in development?

Okay. That's great. That's a very good question. I'm excited to give you an answer. As you know, there are many diseases and like one of them that actually Scentech is focused on is pancreatic cancer. And I'm sure you know that usually, when someone gets a diagnosis of pancreatic cancer, it's usually somewhat late, where it could be Stage IV or it's not a diagnosis that someone wants to hear. Believe it or not, and the technology already exists and has been proven with other diseases, but now the concept of biomarkers that exist in human breast. And there's, of course, not finally proven yet. That's all in the process, but there's good reason to believe based on the science and the research that has been done, that this will help in identifying serious diseases as well like pancreatic cancer, which means coming in way earlier than previously diagnosed, and which just means, whether it means moving to pancreas, whatever has to be done, it's a life and death difference, literally, makes a difference whether a person literally with their breath, actually a painless, simple test that could determine, hey, we better take care of this without any major invest or even worse, people having to go through a therapy but don't know if that will work. So this is major, major, major. And actually, our due diligence team as well, a savvy, very savvy people. And it was -- they were going away themselves. Early detection saves live. That's a given. Everyone knows that and that's what we're at. So we look forward to being both helping the world and that's what the word EZRA means, actually help. But we also helping the company with -- so we're looking forward to some exciting financial rewards for it as well.

[Operator Instructions] And there were no other questions at this time. I would now like to hand the call back to the Reliance Global management team for closing remarks.

Thank you. 2025 represented an important year of progress for Reliance, including a significantly stronger balance sheet with higher cash, improved working capital, increased stockholders' equity and reduced long-term debt. We streamlined the organization through strategic divestitures and continued OneFirm efficiencies, creating a leaner operating structure, while our insurance brokerage and InsurTech platforms remain a stable foundation, generating more than $12 million in commission income during the year. We launched EZRA International Group and Scale51 and have begun executing through our investment in the Enquantum and the intend to acquire a majority stake in Scentech Medical. Overall, we are encouraged by the progress made during the year and remain confident in our ability to continue strengthening the business and delivering long-term value to our shareholders. Thank you for joining us today for our business update. We look forward to speaking with you again on our next call.

Thank you. This does conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.